Tag Archives: Trifluoperazine

Pharmacotherapy in the Treatment of People With Schizophrenia

The pharmacological agents most primarily associated with treatment of schizophrenia are grouped in a large and heterogeneous family, the antipsychotics. Recently, this family has been subdivided into the typicals, or neuroleptics, and the atypicals (see Tables Selected Typical Antipsychotic Drugs and Their Characteristics and Atypical Antipsychotics: Relative Potencies and Side Effects). The neuroleptics are so… Read More »

Adjunctive Pharmacotherapy and Related Issues

Managing antipsychotic side effects. Antipsychotic drugs produce problematic side effects in many individuals (see Table Side Effects of Typical Antipsychotic Drugs). A major category of side effects results from neurotransmitter dysregulation of the extra-pyramidal motor system. It is thought that these side effects are the result of an imbalance of dopaminergic and acetylcholinergic activity in… Read More »

Pharmacological treatment for schizophrenia

Pharmacological treatments are an essential component of a comprehensive approach to the treatment of schizophrenia. Rational pharmacotherapies can contribute greatly to symptom relief and to a broader psychosocial recovery for affected individuals. However, antipsychotic drugs do not cure schizophrenia. Moreover, if not used judiciously, drug therapies can create significant financial, side-effect, and medical morbidity burdens… Read More »

Treatment for Schizophrenia: Antipsychotic Drugs

Modern drug treatment for schizophrenia dates to the early 1950s, when Deniker and Delay reported the antipsychotic effects of chlorpromazine (). Chlorpromazine was introduced in the United States in 1954, followed over the next three decades by several drugs, including fluphenazine, haloperidol, perphenazine, and thioridazine, with similar therapeutic effects. All of these so-called first-generation antipsychotics… Read More »

Neuroleptic treatment of schizophrenia in the elderly

Neuroleptics are commonly used to treat schizophrenia and also exogenic psychosis in elderly patients (). However, there are extremely few methodologically sound controlled trials of neuroleptic drugs in this population, especially of functional psychosis (). Clinical experience and case reports indicate that the efficacy proven in younger schizophrenic patients may be extrapolated to elderly psychotic… Read More »

The pharmaceutical industry and the new drugs

The pharmaceutical industry played a significant part in establishing the role of the new psychiatric drugs in the 1950s and 1960s. For doing so it is sometimes credited with helping transform psychiatry into a modern ‘medical specialism’. The large-scale marketing campaigns that helped to establish the use of the early neuroleptic and antidepressant drugs are… Read More »

Antipsychotic Drugs

Pharmacologic Profile General Use Treatment of acute and chronic psychoses, particularly when accompanied by increased psychomotor activity. Use of clozapine is limited to schizophrenia unresponsive to conventional therapy. Selected agents are also used as antihistamines or antiemetics. Chlorpromazine is also used in the treatment of intractable hiccups. General Action and Information Blockdopamine receptors in the… Read More »

GAD: Recommendations for Treatment

Although many patients with generalized anxiety disorder are not recognized as suffering from a potentially treatable medical condition, it seems probable that most recognized patients receive some form of treatment. The results from the five European centres in the World Health Organization study on Psychological Problems in General Health Care indicate psychotropic drug treatment rates… Read More »

Dopaminergic Agents

Sapropterin • The compound patent was filed in 1980 • Launched in 1982 for the treatment of aminoacidopaty by Daiichi Suntory Pharma • Krishnan et al. from the Duke University have recently described a method for treating serotonergic neuro-transmission dysregulation disorders as e.g. anxiety, by administering sapropterin Trifluoperazine hydrochloride • The first patent for trifluoperazine… Read More »

Antipsychotics For The Treatment Of Schizophrenia

Following the Anatomical Therapeutic Chemical (ATC) classification system by WHO Collaborating Centre for Drug Statistics Methodology), antipsychotics (ATC N05A) are classified as: • N05AA Phenothiazines with aliphatic side-chain: Chlorpromazine, Levomepromazine, Promazine, Triflupromazine, Cyamemazine, Chlorproethazine • N05AB Phenothiazines with piperazine structure: Dixyrazine, Fluphenazine, Perphenazine, Prochlorperazine, Thiopropazate, Trifluoperazine, Acetophenazine, Thioproperazine, Butaperazine, Perazine • N05AC Phenothiazines with piperidine… Read More »